Ribonucleoside 3′-Phosphates as Pro-Moieties for an Orally Administered Drug

ChemMedChem

Volumn 7, Issue 8, 2012, Pages 1361-1364

  Palte, Michael J ^a   Davis, Amy K F ^a   Mcgrath, Nicholas A ^a   Spiegel, Carol A ^b   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antibiotics; Bacteroides fragilis; Metronidazole; Prodrugs; Ribonucleases

Indexed keywords

ADENOSINE 3' (METRONIDAZOLE PHOSPHATE); ANTIBIOTIC AGENT; CYTIDINE 3' (METRONIDAZOLE PHOSPHATE); METRONIDAZOLE; PRODRUG; RIBONUCLEASE; RIBONUCLEASE 1; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; URIDINE 3' (METRONIDAZOLE PHOSPHATE); ANTIINFECTIVE AGENT; PANCREATIC RIBONUCLEASE; RIBONUCLEOTIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; CATALYSIS; DRUG DETERMINATION; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; BACTEROIDES INFECTION; CHEMISTRY; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; HUMANS; KINETICS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PRODRUGS; RIBONUCLEASE, PANCREATIC; RIBONUCLEOTIDES;

EID: 84864396219     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200243     Document Type: Article

References (36)

1. M. Manzano, M. Colilla, M. Vallet-Regi, Expert Opin. Drug Delivery 2009, 6, 1383-1400;
2. C. Maderuelo, A. Zarzuelo, J. M. Lanao, J. Controlled Release 2011, 154, 2-19;
3. X. Rong, Y. Xie, X. Hao, T. Chen, Y. Wang, Y. Liu, Curr. Drug Discovery Technol. 2011, 8, 173-187;
4. J. Pan, S. Y. Chan, W. G. Lee, L. Kang, Biotechnol. J. 2011, 6, 1477-1487;
5. K. Moodley, V. Pillay, Y. E. Choonara, L. C. duToit, V. M. Ndesendo, P. Kumar, S. Cooppan, P. Bawa, Int. J. Mol. Sci. 2012, 13, 18-43.
6. C. A. Lipinski, J. Pharmacol. Toxicol. Methods 2000, 44, 235-249;
7. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, J. Savolainen, Nat. Rev. Drug Discovery 2008, 7, 255-270;
8. S. Jana, S. Mandlekar, P. Marathe, Curr. Med. Chem. 2010, 17, 3874-3908.
9. S. Stegemann, F. Leveiller, D. Franchi, H. deJong, H. Linden, Eur. J. Pharm. Sci. 2007, 31, 249-261.
10. F. J. Sousa, CLAO J. 1991, 17, 282-284;
11. A. T. Bergenheim, R. Henriksson, Clin. Pharmacokinet. 1998, 34, 163-172;
12. M. B. Wire, M. J. Shelton, S. Studenberg, Clin. Pharmacokinet. 2006, 45, 137-168.
13. G. A. Ellis, N. A. McGrath, M. J. Palte, R. T. Raines, ACS Med. Chem. Lett. 2012, 3, 268-272.
14. S. Sorrentino, FEBS Lett. 2010, 584, 2194-2200.
15. M. Kurihara, M. Ogawa, T. Ohta, E. Kurokawa, T. Kitahara, G. Kosaki, T. Watanabe, H. Wada, Cancer Res. 1982, 42, 4836-4841.
16. R. T. Raines, Chem. Rev. 1998, 98, 1045-1065;
17. C. M. Cuchillo, M. V. Nogués, R. T. Raines, Biochemistry 2011, 50, 7835-7841.
18. R. Markham, J. D. Smith, Biochem. J. 1952, 52, 552-557;
19. C. M. Cuchillo, X. Parés, A. Guasch, T. Barman, F. Travers, M. V. Nogués, FEBS Lett. 1993, 333, 207-210;
20. J. E. Thompson, F. D. Venegas, R. T. Raines, Biochemistry 1994, 33, 7408-7414.
21. A. M. Davis, A. C. Regan, A. Williams, Biochemistry 1988, 27, 9042-9047;
22. M. R. Witmer, C. M. Falcomer, M. P. Weiner, M. S. Kay, T. P. Begley, B. Ganem, H. A. Scheraga, Nucleic Acids Res. 1991, 19, 1-4;
23. J. E. Thompson, R. T. Raines, J. Am. Chem. Soc. 1994, 116, 5467-5468;
24. J. K. Stowell, T. S. Widlanski, T. G. Kutateladze, R. T. Raines, J. Org. Chem. 1995, 60, 6930-6936;
25. C. J. Taylorson, H. J. Eggelte, A. Tarragona-Fiol, B. R. Rabin, F. T. Boyle, J. F. Hennam, D. C. Blakey, P. R. Marsham, D. W. Heaton, D. H. Davies, A. M. Slater, L. F. A. Hennequin (Zeneca Ltd., London), US Patent 5985281, 1999.
26. S. Löfmark, C. Edlund, C. E. Nord, Clin. Infect. Dis. 2010, 50, S16-23.
27. M. J. Kasten, Mayo Clin. Proc. 1999, 74, 825-833.
28. M. ChinChung, P. L. Bosquesi, J. L. dosSantos, Curr. Pharm. Des. 2011, 17, 3515-3526.
29. Y. Hayakawa, R. Kawai, A. Hirata, J. I. Sugimoto, M. Kataoka, A. Sakakura, M. Hirose, R. Noyori, J. Am. Chem. Soc. 2001, 123, 8165-8176.
30. Calculator plug-ins were used for structure-property prediction and calculation: Marvin 5.4.1.1, 2011, ChemAxon (Budapest, Hungary).
31. T. Ukita, K. Waku, M. Irie, O. Hoshino, J. Biochem. 1961, 50, 405-415.
32. R. J. Johnson, J. G. McCoy, C. A. Bingman, G. N. Phillips, Jr., R. T. Raines, J. Mol. Biol. 2007, 368, 434-449;
33. J. E. Lomax, C. H. Eller, R. T. Raines, Methods Enzymol. 2012, 502, 273-290.
34. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, Approved Standard, 7th Ed., CLSI Document M11-A7; Clinical and Laboratory Standards Institute, Wayne, PA (USA), 2007.
35. S. L. Wiener, R. Wiener, M. Urivetzky, E. Meilman, Biochim. Biophys. Acta 1972, 259, 378-385;
36. D. D. Blumberg, Methods Enzymol. 1987, 152, 20-24.